DSpace DSpace Softwareについて English
 

GINMU >
01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2024年度 >

このアイテムの引用には次の識別子を使用してください: http://hdl.handle.net/10564/4457

タイトル: Investigating the efficacy of tissue factor pathway inhibitor‑2 as a promising prognostic marker for ovarian cancer
その他のタイトル: 卵巣癌の予後予測マーカーとしての組織経路インヒビター2 の有用性についての検討
著者: Maehana, Tomoka
Kawaguchi, Ryuji
Nishikawa, Kyohei
Kawahara, Naoki
Yamada, Yuki
Kimura, Fuminori
キーワード: ovarian cancer
ovarian clear cell carcinoma
retrospective study
survival rate
predictive factor
tissue factor pathway inhivitor-2
発行日: 2024年5月8日水曜日
出版者: Spandidos Publications
引用: Oncology letters. 2024 May, vol.28, no.1, article no.302
抄録: Abstract. Tissue factor pathway inhibitor‑2 (TFPI2) is a tumor marker for diagnosing ovarian cancer and ovarian clear cell carcinoma (OCCC); however, its effectiveness as a prognostic marker remains unclear. The present study aimed to investigate the utility of TFPI2 as a prognostic marker for ovarian cancer. A total of 256 cases of ovarian cancer was collected at Nara Medical University (Kashihara, Japan) from January 2008 to January 2022. The majority of cases were serous carcinoma (109, 42.6%), followed by OCCC (66, 25.8%), mucinous carcinoma (40, 15.6%), endometrial carcinoma (15, 5.9%), and other (26, 10.2%). The median preoperative serum TFPI2 for ovarian cancer was 219.0 (82.5‑5,824.2) pg/ml. Overall survival (OS) of patients with non‑OCCC and OCCC was calculated using the cut‑off value determined obtained through receiver operating characteristic curve analysis. Cut‑off values of TFPI2 for OS were 201 for non‑OCCC and 255 pg/ml for OCCC. In univariate analysis, OS was significantly elevated in patients with non‑OCCC and OCCC who had TFPI2 levels ≥201 pg/ml (P<0.001) and ≥255 pg/ml (P=0.036), respectively. Progression‑free survival (PFS) was significantly elevated in patients with non‑OCCC and OCCC who had TFPI2 levels ≥201 and ≥255 pg/ml (both P<0.001), respectively. Multivariate analysis revealed that OS was significantly higher in patients with non‑OCCC who had TFPI2 levels ≥201 pg/ml (P=0.021), while PFS was significantly higher in patients with OCCC who had TFPI2 levels ≥255 pg/ml (P=0.020). These findings suggest that TFPI2 is a potential prognostic marker for ovarian carcinoma.
内容記述: 権利情報:© Maehana et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
URI: http://hdl.handle.net/10564/4457
ISSN: 1792-1082
DOI: https://doi.org/10.3892/ol.2024.14435
学位授与番号: 24601甲第962号
学位授与年月日: 2025-03-14
学位名: 博士(医学)
学位授与機関: 奈良県立医科大学
出現コレクション:2024年度

このアイテムのファイル:

ファイル 記述 サイズフォーマット
02甲962本文の要旨.pdf02甲962本文の要旨172.02 kBAdobe PDF見る/開く
03甲962審査要旨.pdf03甲962審査要旨184.87 kBAdobe PDF見る/開く

このリポジトリに保管されているアイテムは、他に指定されている場合を除き、著作権により保護されています。

 

Valid XHTML 1.0! Powered by DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard - ご意見をお寄せください